211 related articles for article (PubMed ID: 12109906)
21. Covalent docking of selected boron-based serine beta-lactamase inhibitors.
Sgrignani J; Novati B; Colombo G; Grazioso G
J Comput Aided Mol Des; 2015 May; 29(5):441-50. PubMed ID: 25676821
[TBL] [Abstract][Full Text] [Related]
22. Structures of the acyl-enzyme complexes of the Staphylococcus aureus beta-lactamase mutant Glu166Asp:Asn170Gln with benzylpenicillin and cephaloridine.
Chen CC; Herzberg O
Biochemistry; 2001 Feb; 40(8):2351-8. PubMed ID: 11327855
[TBL] [Abstract][Full Text] [Related]
23. Functional analyses of AmpC beta-lactamase through differential stability.
Beadle BM; McGovern SL; Patera A; Shoichet BK
Protein Sci; 1999 Sep; 8(9):1816-24. PubMed ID: 10493583
[TBL] [Abstract][Full Text] [Related]
24. Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: mechanistic interpretation of a beta-lactamase transition-state analog.
Lobkovsky E; Billings EM; Moews PC; Rahil J; Pratt RF; Knox JR
Biochemistry; 1994 Jun; 33(22):6762-72. PubMed ID: 8204611
[TBL] [Abstract][Full Text] [Related]
25. 4-Substituted trinems as broad spectrum beta-lactamase inhibitors: structure-based design, synthesis, and biological activity.
Plantan I; Selic L; Mesar T; Anderluh PS; Oblak M; Prezelj A; Hesse L; Andrejasic M; Vilar M; Turk D; Kocijan A; Prevec T; Vilfan G; Kocjan D; Copar A; Urleb U; Solmajer T
J Med Chem; 2007 Aug; 50(17):4113-21. PubMed ID: 17665896
[TBL] [Abstract][Full Text] [Related]
26. Crystal Structures of KPC-2 and SHV-1 β-Lactamases in Complex with the Boronic Acid Transition State Analog S02030.
Nguyen NQ; Krishnan NP; Rojas LJ; Prati F; Caselli E; Romagnoli C; Bonomo RA; van den Akker F
Antimicrob Agents Chemother; 2016 Jan; 60(3):1760-6. PubMed ID: 26729491
[TBL] [Abstract][Full Text] [Related]
27. Structure-based optimization of a non-beta-lactam lead results in inhibitors that do not up-regulate beta-lactamase expression in cell culture.
Tondi D; Morandi F; Bonnet R; Costi MP; Shoichet BK
J Am Chem Soc; 2005 Apr; 127(13):4632-9. PubMed ID: 15796528
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Acinetobacter-Derived Cephalosporinase: Exploring the Carboxylate Recognition Site Using Novel β-Lactamase Inhibitors.
Caselli E; Romagnoli C; Powers RA; Taracila MA; Bouza AA; Swanson HC; Smolen KA; Fini F; Wallar BJ; Bonomo RA; Prati F
ACS Infect Dis; 2018 Mar; 4(3):337-348. PubMed ID: 29144725
[TBL] [Abstract][Full Text] [Related]
29. Selective trihydroxyazepane NagZ inhibitors increase sensitivity of Pseudomonas aeruginosa to β-lactams.
Mondon M; Hur S; Vadlamani G; Rodrigues P; Tsybina P; Oliver A; Mark BL; Vocadlo DJ; Blériot Y
Chem Commun (Camb); 2013 Dec; 49(93):10983-5. PubMed ID: 24136176
[TBL] [Abstract][Full Text] [Related]
30. Structure-based approach for identification of novel phenylboronic acids as serine-β-lactamase inhibitors.
Sgrignani J; De Luca F; Torosyan H; Docquier JD; Duan D; Novati B; Prati F; Colombo G; Grazioso G
J Comput Aided Mol Des; 2016 Oct; 30(10):851-861. PubMed ID: 27632226
[TBL] [Abstract][Full Text] [Related]
31. Noncovalent interaction energies in covalent complexes: TEM-1 beta-lactamase and beta-lactams.
Wang X; Minasov G; Shoichet BK
Proteins; 2002 Apr; 47(1):86-96. PubMed ID: 11870868
[TBL] [Abstract][Full Text] [Related]
32. Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant.
Sun T; Bethel CR; Bonomo RA; Knox JR
Biochemistry; 2004 Nov; 43(44):14111-7. PubMed ID: 15518561
[TBL] [Abstract][Full Text] [Related]
33. Crystal structures of the class D beta-lactamase OXA-13 in the native form and in complex with meropenem.
Pernot L; Frénois F; Rybkine T; L'Hermite G; Petrella S; Delettré J; Jarlier V; Collatz E; Sougakoff W
J Mol Biol; 2001 Jul; 310(4):859-74. PubMed ID: 11453693
[TBL] [Abstract][Full Text] [Related]
34. Structural Insights into Inhibition of the Acinetobacter-Derived Cephalosporinase ADC-7 by Ceftazidime and Its Boronic Acid Transition State Analog.
Curtis BN; Smolen KA; Barlow SJ; Caselli E; Prati F; Taracila MA; Bonomo RA; Wallar BJ; Powers RA
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988830
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of class A and class C beta-lactamases by penems: crystallographic structures of a novel 1,4-thiazepine intermediate.
Nukaga M; Abe T; Venkatesan AM; Mansour TS; Bonomo RA; Knox JR
Biochemistry; 2003 Nov; 42(45):13152-9. PubMed ID: 14609325
[TBL] [Abstract][Full Text] [Related]
36. Structural milestones in the reaction pathway of an amide hydrolase: substrate, acyl, and product complexes of cephalothin with AmpC beta-lactamase.
Beadle BM; Trehan I; Focia PJ; Shoichet BK
Structure; 2002 Mar; 10(3):413-24. PubMed ID: 12005439
[TBL] [Abstract][Full Text] [Related]
37. Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative.
Tondi D; Venturelli A; Bonnet R; Pozzi C; Shoichet BK; Costi MP
J Med Chem; 2014 Jun; 57(12):5449-58. PubMed ID: 24882105
[TBL] [Abstract][Full Text] [Related]
38. Using steric hindrance to design new inhibitors of class C beta-lactamases.
Trehan I; Morandi F; Blaszczak LC; Shoichet BK
Chem Biol; 2002 Sep; 9(9):971-80. PubMed ID: 12323371
[TBL] [Abstract][Full Text] [Related]
39. Structure-based design of a potent transition state analogue for TEM-1 beta-lactamase.
Strynadka NC; Martin R; Jensen SE; Gold M; Jones JB
Nat Struct Biol; 1996 Aug; 3(8):688-95. PubMed ID: 8756327
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in the chemistry of beta-lactam compounds as selected active-site serine beta-lactamase inhibitors.
Mascaretti OA; Danelon GO; Laborde M; Mata EG; Setti EL
Curr Pharm Des; 1999 Nov; 5(11):939-53. PubMed ID: 10539998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
